

Supplemental Table. Metastasis risk modifiers by surveillance protocols

Feature	Standard Protocol vs Enhanced Protocol			Standard Protocol vs High Frequency			Standard Protocol vs Enhanced Modality		
	Standard Protocol (n = 11 ¹)	Enhanced Protocol (n= 76 ¹)	p-value ²	Standard Protocol (n = 11 ¹)	High Frequency (n = 54 ¹)	p-value ²	Standard Protocol (n = 11 ¹)	Enhanced Modality (n = 64 ¹)	p-value ²
Age (years)	57 (50, 70)	63 (58, 70)	0.2	57 (50, 70)	63 (58, 69)	0.3	57 (50, 70)	64 (58, 70)	0.3
Sex (Male/Female)	7/4	37/39	0.4	7/4	27/27	0.4	7/4	30/34	0.3
Tumor location			0.3			0.2			0.3
Choroid only	10 (91%)	53 (70%)		10 (91%)	35 (65%)		10 (91%)	45 (70%)	
CBD +/- choroid	1 (9.1%)	23 (30%)		1 (9.1%)	19 (35%)		1 (9.1%)	19 (30%)	
LBD (mm)	13.0 (11.0, 15.8)	15.0 (11.0, 16.5)	0.6	13.0 (11.0, 15.8)	15.3 (11.3, 16.9)	0.5	13.0 (11.0, 15.8)	15.0 (11.0, 16.5)	0.6
Tumor thickness (mm)	6.7 (2.6, 10.0)	6.1 (3.8, 9.0)	0.9	6.70 (2.60, 9.95)	6.25 (4.00, 9.00)	0.9	6.7 (2.6, 10.0)	6.3 (3.7, 9.0)	0.9
PRAME status (+)	3 (60%)	21 (48%)	0.7	3 (60%)	19 (56%)	>0.9	3 (60%)	20 (50%)	>0.9

¹Median (IQR); n (%)

²Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

CBD: Ciliary body; LBD: Largest basal diameter